Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Summary

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP

Timeline

Start

2022-02-02

Primary completion

2028-08-02

Completion

2028-08-02

Drugs

Indications